Cosentyx (Secukinumab) Patent Expiration, LOE Window & CMS Spending

Cosentyx (Secukinumab) by Novartis: Biologic BLA (Purple Book Regime), 0 AB generics, $3.1M 2024 CMS Part D & Medicaid spend, and 21 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayB125504 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.1M
2024 Medicare Part D Spend$1.1M
2024 Medicaid Spend$2.0M
Reported Wholesale Price Change (CA SB 17)21 WAC filings (max 24.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.